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ABSTRACT: This article is an account of a screening programme in search of new antibiotics 
established by CEPA (Compañia Española de Penicilinas y Antibióticos) and Merck in Madrid 
in 1954. An exploration of the genealogy for such a programme, its narratives and practices, 
shows that the main inspiration for this programme was the factory system of production, 
on the one hand, and Selman Waksman’s research agenda on microorganisms of the soil, 
on the other. In this article, the relationship between industrial production of antibiotics 
and the research program aimed at identifying new candidate drugs is examined. I suggest 
that this screening program in search of new antibiotics was organised like industrial ma-
nufacturing. The research objects and tools came, both materially and conceptually, from 
industrial production: a line of artisanship put together in order to obtain a product with 
the collaboration of every member of the production line. Following the style developed by 
Selman Waksman in Rutgers, the screening program evaluated samples manually, and the 
microbiological skills were enhanced with every test. The Madrid team’s practice of applying 
instructions for use led to circulation of knowledge and practices, including research material 
and microbiological methods.
 KEY WORDS: Antibiotic screening, CEPA, Spain, factory system and research, Antonio Gallego, 
Selman Waksman. 
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1. Introduction (*)
Drugs standards, the norms and values of their wonders, belonged and 
may still belong to an idea of creation and invention closely related to the 
way of production shown in Modern Times (Charles Chaplin, 1936). Just 
as industrial production was done on the assembly-line, interconnections 
of related mechanisms generated products, health standards, ways of 
inventing and styles of looking at nature. Meanwhile, the production of 
drugs led to a systematic way of searching for them. This systematization 
created standards which circulated from one place to another. This was the 
case when a program to search for new antibiotics was set up in Madrid 
in the early 1950s.
It was during the 1950s when Spain began to recover from the devastating 
effects of the civil war and of the early decade of Franco’s dictatorship, 
during which hunger and poverty combined with corruption and the black 
market of basic products —bread and drugs among them— during the 
isolation from abroad 1. This isolation was double as it was composed of: 
Franco dictatorship autarchy as a policy for promoting national production 
and by the policy of the allies toward the dictatorship, which prevented 
Spanish membership in the international organizations that emerged right 
after the Second World War 2.
The Spanish firm created to manufacture penicillin, CEPA, was a 
combination of firms which were dedicated to production of chemicals, 
an industrial bank, Banco Urquijo, and Merck (Rahway), which signed an 
agreement to collaborate in building the factory and in the manufacturing 
 (*) The research for this article was funded by the Spanish ministry of Science and Innovation 
(FFI2009-07522) and benefited of the ESF Research networking program DRUGS by presenting 
it in one of its workshops.
 1. Del Cura, Isabel; Huertas, Rafael. Alimentación y enfermedad en tiempos de hambre: España, 
1937-1947. Madrid: Consejo Superior de Investigaciones Científicas; 2007. Cazorla, Antonio. 
Las políticas de la victoria: la consolidación del Nuevo Estado franquista (1938-1953). Madrid: 
Marcial Pons; 2000. Catalán, Jordi. La economía española y la segunda guerra mundial. Bar-
celona: Ariel; 1995. Camprubí, Lino. One grain, one nation: rice genetics and the corporate 
state in early Francoist Spain (1939-1952). Historical Studies in the Natural Sciences. 2010; 
40: 499-531.
 2. Portero, Florentino. Franco aislado. La cuestión española (1945-1950). Madrid: Aguilar; 1989. 
Guirao, Fernando. Spain and the reconstruction of Western Europe, 1945-57. Londres: Mac-
Millan; 1998.
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process of penicillin in 1948 3. Industrial policy of the Franco dictatorship 
established a tax on the benefits of every industrial firm in the 1940s, which 
in the case of the iron, steel and concrete industry was between 0.5 and 1 
percent of sales. In other cases, the contribution was considered a donation, 
although it was in fact a hidden tax. Those funds were dedicated to so-
called applied research, some of them invested in useless projects, others 
promoting research in organic chemistry, for example. Those taxes became 
some of the main funding for applied research at the Consejo Superior de 
Investigaciones Científicas (CSIC), the research institution created by Franco 
right after the Civil War 4. In spite of the arbitrary power of dictatorship 
authority and nepotism practices, some negotiation became possible for 
those close to the decision-making process in Madrid. Thus, instead of 
donating a percentage of its benefits, CEPA created a research centre at the 
University of Madrid Faculty of Medicine, the Instituto de Farmacología 
Española (IFE), initially dedicated to physiology, the discipline in which 
the director of CEPA, Antonio Gallego, was a professor. Gallego’s interest 
in research was wider, however, and became the origin of a negotiation 
with Merck, after the building of the penicillin factory, which led to a new 
program in search of new antibiotics which ran from 1954 onwards 5.
Norms and policies of the Franco dictatorship combined with foreign 
industrial relationships to provide means and grounds for experimental 
research 6. In the case of the program whose creation is explored here, the 
 3. On penicillin production in Spain and the features of the dictatorship, see Santesmases, María 
Jesús. Delivering penicillin: the clinic, the hero and industrial production in Spain, 1943-1952. 
In: Quirke, Vivian; Slinn, Judy, eds. Perspectives on twentieth century pharmaceuticals. Oxford: 
Peter Lang; 2010, p. 91-117. On history of the pharmaceutical industry in Spain see also 
Puig, Nuria. Networks of innovation or networks of opportunity? The making of the Spanish 
antibiotics industry. Ambix. 2004; 51: 167-185.
 4. López García, Santiago. El saber tecnológico en la política industrial del primer franquismo 
[doctoral thesis]. Universidad Complutense; 1994. López García, Santiago. La investigación 
científica y técnica antes y después de la guerra civil. In: Gómez Mendoza, Antonio, ed. 
Economía y sociedad en la España moderna y contemporánea. Madrid: Síntesis; 1996.
 5. Santesmases, María Jesús. Entre Cajal y Ochoa: ciencias biomédicas en la España contemporánea. 
Madrid: CSIC; 2001, chapter 4. 
 6. I have explored elsewhere research activity in Spain as a combination of national policies and 
foreign collaboration and influence. See for example Santesmases, María Jesús. Severo Ochoa 
and the biomedical sciences in Spain under Franco, 1959-1975. Isis. 2000; 91: 706-734, and 
Santesmases, María Jesús. Orígenes internacionales de la política científica. In: Romero, Ana; 
Santesmases, María Jesús, eds. Cien años de política científica en España. Madrid: Fundación 
Banco Exterior; 2008, p. 293-327.
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interest of CEPA to have a research activity at the Spanish firm which was 
manufacturing penicillin appears to have coincided with the interest of 
Merck in diversifying its research activities while also keeping active its 
line of research for new antibiotics started by Selman Waksman. 
This article is an account of a screening programme in search of new 
antibiotics established by Merck (Rahway) and CEPA (Compañía Española 
de Penicilinas y Antibióticos — Madrid) in 1954. An exploration of the 
genealogy for such a programme, its narratives and practices, shows that the 
main inspiration for this programme was the factory system of production, 
on the one hand, and Selman Waksman’s research agenda on microorganisms 
of the soil, on the other. 
In this article, the relationship between industrial production of 
antibiotics and the research program aimed at identifying new candidate 
drugs is examined. I suggest that the screening program in search of new 
antibiotics was organised industrially. Research was motivated and organised 
according to industrial management. This case could be described as a 
counter-linear model. That is, it shows the origins of research in the factory 
instead of the opposite, which would have been building the factory after 
some research was carried out 7.
The research program analysed here included training, personal 
instructions and repeated manipulations while keeping laboratory skills at the 
core of work place practices. Instead of being like the invisible industrialists 
analyzed by Ilana Löwy and Jean-Paul Gaudillière, the researchers of CEPA 
were visible. They were as visible as the factory in which they worked, 
developed a research project and assembled a line of production of samples 
whose antimicrobial activity would be detected. Research objects and tools 
of this screening program in search of antibiotics came, both materially and 
conceptually, from industrial manufacturing 8. And it was in the factory 
where the research program and the materials and research participants 
 7. On the linear model, from research to industrial production, see the contributions to Part I in 
Grandin, Karl, Nina Wormbs, Sven Widmalm, eds. The science-industry nexus. History, policy, 
implications. Sagamore Beach: Science History Publication; 2004. See also in Hulverscheidt, 
Marion A. The scientific entrepreneur or financing in pharmaceutical research. A portrait of 
the mariologist Werner Schulemann, 1888-1975. In: Quirke; Slinn, n. 3, 121-148. This is an 
account of research done at a research laboratory by a scientist who had started his career 
at an industrial laboratory.
 8. See the contributions to Löwy, Ilana; Gaudillière, Jean-Paul, eds. Invisible industrialist. Manu-
factures and the production of scientific knowledge. London: MacMillan Press; 1998.
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occupied physical space. The research was part of the factory itself and 
followed industrial patterns of action. So it was not only that devices used 
had been manufactured by an industrial firm and became part of the work 
at the bench; it was that the design of the research program itself was a 
product of an industrial project, that of producing antibiotics in Spain.
Samples screening was the practice at Selman Waksman laboratory at 
Rutgers University. The routine of repeated manipulation of soil samples 
in search of new Actinomycetes was far from being the «uncreative testing 
techniques» Kingston talks about 9. Samples were evaluated manually, 
and the microbiological skills were enhanced with every test. By applying 
instructions for use, by following recipes elaborated somewhere else, the 
Madrid team’s work was a product of the circulation of knowledge and 
practices. It showed training and knowledge production in microbiology 
and industrial manufacturing style through the circulation of research 
material and methods of microbiology.
2. The factory system and industrialised research 
In studying this screening programme, two features should be stressed. 
One is the fact that a research initiative was set up right after the creation 
of a factory for penicillin manufacturing in Madrid 10. This special case of 
research emerging from a factory gave the screening program the same 
characteristics as a factory system. The research for new antibiotics was an 
assembly line of tasks done under supervision. And it was indeed part of a 
process of industrialisation, which at that particular time in Madrid meant 
building factories to make products in Spain whose production process was 
patented abroad. That is, manufacturing procedures were brought from a 
U.S. firm to a Spanish firm 11.
 9. Kingston, William. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. 
Journal of the History of Medicine and Allied Sciences. 2004; 59: 441-462, where it is stressed 
the repetitive nature of Waksman’s screening so as to reinforce Waksman’s authority and thus 
wresting authority from collaborators of him like Albert Schatz, with whom priority conflicts 
arose regarding streptomycin. On this see also Wainwright, Milton. Streptomycin: discovery 
and resultant controversy. History and Philosophy of the Life Sciences. 1991; 13: 97-124.
 10. Santesmases, n. 4.
 11. On technology transfer from abroad into Spain see Cebrián, Mar. Technological imitation and 
economic growth during the Golden Age in Spain: 1959-1973 [doctoral Thesis] Florence: 
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Previous pharmaceuticals produced in Spain were vaccines and sera, 
both made during the first third of the 20th century at the Instituto de 
Higiene created and funded by the State, and in private firms. The chemical 
industry was dependent on supplies bought abroad: dyestuffs and fertilizers 
were also bought abroad for the textile industry 12. Thus, the trajectory of 
Ehrlich in the pharmaceutical industry, which led to salvarsan, prontosil 
and sulfa drugs from dyes, was an exception that helps to explain the 
developments of the German pharmaceutical industry coming from the 
chemical industry 13. The case presented here shows a path from industry 
to research; research was a result of industrial production, a product of 
industrialisation. The research area was microbiology, that is, expertise in 
handling and isolating microbes and their prospective antagonists. 
Training in microbiology and culturing techniques took place during the 
process of creating and setting up a screening program for new antibiotics 14. 
Doing research in microbes screening in search of new antibiotics was in 
tune with the rhetoric of the time, which put research as the path toward 
economic recovery and industrial development that was predominant in 
the West from post-Second World War and throughout the Cold War 15.
European University Institute; 2004. Also López, Santiago; Cebrián, Mar. Economic growth, 
technology transfer, and convergence in Spain, 1960-1973. In: Ljunberg, Jonas; Smits, Jan-
Pieter, eds. Technology and human capital in historical perspective. New York: Palgrave-
Macmillan; 2004, p. 120-144. On the factory system of production from the point of view of 
the history of economics and industry see Chapman, Stanley D. The textile factory before 
Arkwright: a typology of factory development. Business History Review. 1974; 48: 451-478. 
Carlsson, Bo. The development and use of machine tools in historical perspective. Journal of 
Economic Behaviour and Organisation. 1984; 5: 91-114. Mokyr, Joel. The rise and fall of the 
factory system: technology, firms and households since the industrial revolution. Carnegie-
Rochester Conference series on Public Policy. 2001; 55: 1-45. Geraghty. The factory system 
in the British industrial revolution: A complementarity thesis. European Economic Review. 
2007; 51: 1329-1350.
 12. Puig, Nuria. El crecimiento asistido de la industria química en España: Fabricación nacional de 
colorantes y explosivos, 1922-1965. Revista de Historia Industrial. 1999; 15: 105-136. And also 
Puig, Nuria; Loscertales, Javier. Las estrategias de crecimiento de la industria química alemana 
en España, 1880-1936: exportación e inversión directa. Revista de Historia Económica. 2001; 
19: 345-382.
 13. Lesch, John. The first miracle drugs. How sulfa-drugs transformed medicine. Oxford-New York: 
Oxford University Press; 2007.
 14. On culturing techniques of human tissues, see Landecker, Hanna. Culturing life: how cells 
became technologies. Cambridge, MA: Harvard University Press; 2007. 
 15. OECD 1961; and Santesmases 2008, n. 6.
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It was also the era of screening, of systematically testing cultures, samples 
and techniques in order to find better ways for diagnosis and treatments 16. 
It was a time of great hope regarding a world without infections. There 
was an interaction between industrialisation, as a way of distributing 
work along an assembly line, and that of screening as a testing assembly 
line, of systematically looking for antimicrobial activity in samples from 
which an antibiotic could be detected and isolated. It was as if the way of 
screening, as such, was modelled on industrial organisation. Not only was 
there a sequence of tasks, but also an integrated set of procedures aimed 
at mass-producing new samples of antibiotics. Both means —a production 
line— and aims —mass-production— permits characterizing the screening 
program in search of new antibiotics as a factory system 17.
In the case presented here, screening was understood as a lineal way 
of making tests, getting evidence and finding proof, either of the presence 
or the absence of something. In this sense, John Lesch’s book, The First 
Miracle Drug, is suggestive, and convincing, regarding the instrumental 
role played by research on sulfa drugs development, as it created a culture 
of systematically testing reagents which might add a functional group to 
a molecule whose therapeutic effect could increase while decreasing its 
toxicity. Although not called screening, it was a system of production of 
prospective new anti-infective chemical products.
Microbes cultures, however, were different. Their handling required 
particular skills and different sensitivity. And they did not have the technical 
requirements that organic and biological chemistry of dyestuffs and sulfa 
derivatives had 18. Activity was what was identified instead of structure, or 
any further chemical characterisation such as chemical composition and 
prospective chemical synthesis. Even if systematised, microbiological practices 
of screening evoked artisanal work: careful looking at microbe cultures, at 
the rings around them, their shape and intensity. Chemical identification, 
 16. See the screening of viral particles for the treatment of human cancer in the 1950s in Gaudil-
lière, Jean-Paul. Circulating mice and viruses: The Jackson Memorial Laboratory, The Cancer 
Institute and the genetics of Breast Cancer, 1930-1965. In: Fortun, Michael; Mendelsohn, 
Everett, eds. The practices of human genetics. Dordrecht-Biston: Kluwer; 1999. On the screen-
ing of cervical cancer, see Löwy, Ilana. Preventive strikes. Women, precancer and prophylactic 
surgery. Boston: Johns Hopkins University Press; 2010.
 17. On the factory system in historical perspective see n. 11.
 18. Bud, Robert. The uses of life. Cambridge: Cambridge University Press; 1993. On fermentation 
in history of antibiotics see Bud, this volume.
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on the other hand, evokes post-industrial technology as it was mediated 
by a diversity of devices. Screening as a term was indeed used for those 
techniques of searching for antagonists of microbes. 
In the screening program set up jointly by Merck and CEPA in 
Madrid, the tasks of the CEPA laboratory were basically microbiological. 
It included collecting soil samples and the isolation of microbes whose 
antibiotic capacity would be tested against a list of known bacteria. The 
preparation of concentrated samples of the antimicrobial and its toxicity 
characterisation would be the aim of the research work in Madrid. Further 
chemical identification of the active product in the extract would be done 
at Merck Research Laboratories in Rahway (New Jersey). 
The identification of antibiotic capacity of the sample and the 
characterisation of microbes of the species Actinomycetes included careful 
handling of Petri dishes and looking at the ring which might surround an 
active sample. Merck, meanwhile, concentrated on the more highly-technical 
skills of chemical isolation and identification of composition and structure, 
and on the synthesis needed for this as well. Even if microbiology came to 
replace chemistry as the discipline involved in finding new antibiotics from 
penicillin onwards, chemistry remained a remarkable area of expertise in 
drugs research and production.
3. Selman Waksman’s research agenda
Soil microbiology was Waksman’s early research project as a graduate student, 
the subject by which many of his students were introduced to research, and 
the platform from which systematic research on the antagonistic action of 
soil microbes took place. This eventually led to the finding of streptomycin 
at Rutgers, in a collaborative project with Merck (Rahway) 19.
The collaboration between Merck and Waksman started in 1938 when 
Merck hired Waksman as a consultant and established a fellowship in 
fermentation studies at Waksman’s laboratory 20. Together with Woodruff, 
they found an antibiotic from Actinomycetes which proved to be highly toxic 
 19. Accounts of these events are in Wainwright n. 9, and Kingston n. 9. 
 20. Lechevalier, Hubert. The search of antibiotics at Rutgers University. In: Parascandola, John, 
ed. The history of antibiotics. A symposium. Madison: American Institute of the History of 
Pharmacy; 1980, p. 113-123
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to experimental animals. As a result, according to Waksman’s recollections, 
a «comprehensive programme of screening Actinomycetes» ensued, as they 
had noticed that there was a diversity of antibiotics to be found among 
Actinomycetes in terms of antimicrobial activity, chemical features and 
toxicity to animals. As penicillin left the gram-negative bacteria «gap», the 
main challenge was to obtain antagonists of those bacteria 21.
These biological products were everywhere in Waksman’s research 
landscape. Actinomycetes were the microorganism that Waksman knew 
best. By the 1910s, Waksman with R. E. Curtis had obtained «hundreds» 
of Actinomycetes from soils. They were «fascinated» by their structure and 
function and, once they had been characterised, they established the bases 
for regarding such microorganisms as ones that limited bacterial growth 
in soil through what was called their «antagonistic nature», the capacity 
of one microorganism to kill others, an idea that is at the very heart of 
bacteriology 22. By then, Waksman was a lecturer on soil bacteriology at 
Rutgers Agricultural College, and his research agenda revolved around what 
could be called soil ecology; that is, the study of the relationship between 
different types of microorganisms in the soil 23.
4. Industrial connection
The relationship between Merck and Selman Waksman’s laboratory developed 
over the years. Some former Waksman students were hired by Merck’s 
research laboratories, whose facilities were available for any development 
the Rutgers group might make at the University 24. The earliest patenting 
results were those of Waksman and Schatz on streptomycin in 1943, 
which turned out to be active against «certain forms» of tuberculosis and 
 21. Waksman, Selman. Streptomycin: background, isolation, properties, and utilization. Nobel 
Lecture, Dec 12, 1952, p. 370-388.
  At http://nobelprize.org/nobel_prizes/medicine/laureates/1952/waksman-lecture.pdf .
 22. Woodruff, H. Boyd. Selman Waksman. Historical background. Annals of the New York Academy 
of Sciences. 1960; 89: 287-298.
 23. Sakula, Alex. Selman Waksman 1888-1973, discoverer of streptomycin: a centenary review. 
British Journal of Disease of the Chest. 1988; 82: 23-31.
 24. Galambos Louis. Values & visions: A Merck century. Rahway: Merck and Co; 1991, p. 74.
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Hemophilus among others, and of Waksman and Harold Boyd Woodruff 
on actinomycin 25. 
By then, and on the basis of an agreement with Rutgers, Merck held 
patent rights for the production of all substances identified and isolated 
in the framework of this agreement, and of some others as well (whereby 
research funds from Merck were granted to Waksman’s laboratory to search 
for new antibiotics). Later on, Waksman renegotiated the agreement: Rutgers 
obtained patent rights on both antibiotics, streptomycin and actinomycin, 
and Merck accepted a non-exclusive license to produce streptomycin 26.
After taking part in the war effort for the efficient production of 
penicillin, Merck (Rahway) became the owner of patent rights to produce 
penicillin and streptomycin and started to license them outside the U.S. This 
was the arena for Merck’s relationship with Spain at that time. Through a 
commercial agreement signed in 1948, a new firm was set up by a group 
of Spanish chemical and pharmaceutical companies which belonged to 
Banco Urquijo (a Spanish merchant bank) after entering into a contract 
with Merck (Rahway) to build a penicillin production plant in Madrid 27.
At that time, the research group led by Waksman at Rutgers University 
had successfully developed «a comprehensive programme of screening 
Actynomicetes for their ability to produce different antibiotics», a programme 
envisaged after reading the early papers on the antibacterial activity of 
penicillin extracts 28. They obtained collections of soil samples, plated 
them out, isolated Actinomycetes and tested them for antibiotic activity 
against non-pathogenic strains of mycobacteria over and over again in 
the hope of finding new substances active against pathogenic strains 29. 
This seemingly simple project, whose description may evoke routine and 
repetitive activity, was dutifully maintained at Waksman’s laboratories 
even in the 1950s, when a perception spread that no new antibiotics were 
 25. For a list of diseases responding to streptomycin see Waksman, n. 21, p. 383-384. The activity 
of streptomycin in the treatment of penicillin was widely celebrated at its time. See Comroe, 
Julius H. Pay dirt: the story of streptomycin part II. Feldman and Hinshaw; Lehmann. American 
Review of Respiratory Disease. 1978; 117: 957-968.
 26. Lechevalier, n. 20.
 27. Santesmases, n. 3. Copies of the agreements are at the Archivo General de la Administración, 
Industria, Alcalá de Henares, Madrid.
 28. Woodruff, H. Boyd. Natural products from microorganism. Science. 1980; 208: 1225-1229.
 29. Waksman, n. 21.
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needed, taking into account the number of them already being isolated, 
identified and manufactured  30.
However, the increasing resistance of bacteria to the activity of many 
antibiotics spurred on the search for new ones. The systematic research 
on soil preparations as a repetitive, planned programme was part of a 
microbiological strategy, closely associated to the meaning of «antibiotic» 
as a term coined by Waksman himself 31. According to his own narrative, 
this research program began to yield time and again the same antibiotics 
that were already known, as the same one could be produced by different 
species 32. «At this point, a more creative research approach to screening 
becomes essential» 33.
Previous commercial agreements between Merck and CEPA were 
managed by the director of CEPA, Antonio Gallego. The Spanish market, 
the Spanish public, and Franco’s dictatorship were more than a mere context 
for the dissemination of therapeutic success of penicillin and its industrial 
manufacturing in Spain. During the second decade of Franco’s dictatorship, 
penicillin functioned as a heroic medical and scientific object as well as 
a State-controlled product. It saved lives but was also embedded in the 
regime’s bureaucracy 34.
Once the penicillin factory in Madrid was manufacturing the drug, 
Gallego suggested «a new research endeavour» at CEPA’s laboratories 
using fees from penicillin and streptomycin manufacturing licences 35. 
The documents on the agreement, as well as testimonies provided by his 
former collaborators at CEPA, suggest that Gallego was fully aware of the 
research programme developed by the Merck Research Laboratory and 
 30. In 1952, forty-four antibiotics were listed by Spector, William, ed. Handbook of biological data. 
Philadelphia-London: W.S. Saunders Co.; 1952. Se also Lechevalier, n. 20.
 31. Waksman, Selman. What is an antibiotic or antibiotic substance? Mycologia. 1947; 39: 565-
569. On antibiotic as a brand, see Bud, Robert. From Germfobia to carefree life and back 
again. The lifecycle of the antibiotic brand. In: Tone, Andrea; Watkins, Elizabeth Siegel, eds. 
Medicating modern America: prescription drugs in history. New York: New York University 
Press; 2007, p. 17-41.
 32. Waksman, n. 21. 
 33. Woodruff, H. Boyd; Hernández, Sebastián; Stapley Edward O. Evolution of an antibiotic screen-
ing programme. A tribute to Justo Martínez Mata. Hindustan Antibiotics Bulletin. 1979; 21: 
71-84.
 34. Santesmases, n. 3.
 35. Strohl, W. R.; Woodruff, H. B.;  Monaghan, R. L. et al. The history of natural products research at 
Merck & Co., Inc. SIM News. 2001; 51: 5-19. 
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Merck Institute for Therapeutic Research, set up in 1938 36. From his early 
contact with Merck in 1947 as the representative of the Spanish bank which 
had signed the agreement for manufacturing penicillin in Spain, Gallego’s 
relationship with Merck successfully developed. 
The research collaboration also came about, at least in part, to fulfil 
the requirements of the State concession to Banco Urquijo for producing 
penicillin in Spain: the firm was required by the concession decree to conduct 
research on Spanish sources for antibiotics 37. Research facilities were built 
in one of the factories. Scientific personnel from CEPA recall that part of 
the quality control department was used for that purpose.
By the time of the signing of the agreement, in September 1954, a 
streptomycin production plant was working all-out. Waksman came to 
Madrid for the inauguration on the tenth anniversary of the «discovery» 
of the drug, according to the 1954 CEPA annual report 38.
5. Setting tasks for «screening»
The contract signed in 1954 stated that CEPA wished to set up an 
antibiotic screening programme aimed at the discovery and development 
of antibiotics 39. What screening meant at that exact point was not clear to 
the young microbiologist who applied for a post in the CEPA laboratory, 
Sagrario Mochales 40. It appears to have been used by Merck and CEPA for 
this particular project aimed at systematically testing soil samples in search 
of Actinomycetes possessing antibiotic activity. The programme consisted of 
a search for new antibiotics active against gram-negative bacteria. At that 
time Merck was interested in broadening the search for new antibiotics «but 
 36. Swann, John P. Academic scientists and the pharmaceutical industry: cooperative research in 
twentieth-century America. Baltimore: Johns Hopkins University Press; 1988. 
 37. Boletín Oficial del Estado [Official State Gazette] 11 Aug 1949, decree dated 17 June.
 38. Fondos Servicio de Estudios del Banco Urquijo, Instituto Juan March de Investigaciones Sociales 
Avanzadas, Madrid. I would like to thank Antonio Gómez Mendoza for his advice in consult-
ing this archive. 
 39. Agreement made and entered into as of the 14th of January 1949 between Merck & Co., Inc 
and Banco Urquijo. Contracts 37QC, boxes 5112 and 5113, IDD 1.04. Ministerio de Industria. 
Sección de Subsecretaría (Asistencia Técnica), Archivo General de la Administración (AGA), 
Alcalá de Henares, Madrid (in English in the original). I would like to thank Mar Cebrián for 
her guidance in consulting these files at the AGA.
 40. Mochales interview 1994.
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the cost of doing so and the interference with ongoing research projects, 
were inhibitory» 41. An opportunity arose when Antonio Gallego suggested a 
collaborative research project. H. Boyd Woodruff was head of the research 
section and later director of the department of microbiology and natural 
products isolation at Merck in Rahway. Woodruff had trained with Selman 
Waksman at Rutgers, with whom he published papers on microorganisms 
isolated from the soil during the 1940s, before being hired by Merck.
According to remembrances of Gallego’s collaborators, it was at 
Gallego’s initiative that the research program was established in Madrid. 
Apparently, for Merck it was an opportunity to initiate new research in 
Rahway, including the program to develop drugs to destroy the microbial 
plaque attached to teeth and the one to explore the antigenic properties 
of bacterial polysaccharides 42. 
The purpose of the cooperative project established between CEPA and 
Merck was to look for new soil samples, samples from other soils, collected 
everywhere «by Merck sales agents» and sent to Madrid to be tested for 
their antagonist activity. CEPA’s scientific director, Antonio Gallego, was 
involved early on in Madrid and, with Randolph T. Major from Merck 
Research Laboratories, formalised the cooperation agreement. Lloyd F. 
McDaniel (Merck) and Justo M. Mata (CEPA) were appointed as directors 
of the programme 43. 
In order to search for new antibiotics in new soils, the Spanish group had 
to learn the culturing techniques, the method of treatment of the samples 
and ways of testing them. CEPA medical researcher Sebastián Hernández 
went to the Merck Research Laboratories in Rahway to be trained in the 
programme’s laboratory practices. Laboratory equipment, reagents and 
methods for isolating and testing the soil extracts were «transferred» from 
Rahway to Madrid, and McDaniel and Woodruff travelled there frequently, 
particularly during the period when the laboratory and the screening line 
were being assembled. An exchange of visits took place during the early 
stages of the programme until it was completely set up according to Merck 
standards 44.
 41. Strohl et al., n. 35, p. 9.
 42. Woodruff, n. 28.
 43. Strohl et al, n. 35. 
 44. Mochales interview. See also Mochales, Sagrario. Ten years of CIBE symposia, 1989-1998. Inter-
national Microbiology. 1998; 1: 251-254.
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By 1956, the activity of the programme at the CEPA research laboratory 
in Madrid included: isolation of Actinomycetes, testing the isolates against 
a set of bacterial products, development of active cultures in shake flasks, 
resistance test of broths and determination of antibacterial spectrum, further 
production in 5-litre flasks and confirmation of previous identification (if 
any), preparation of concentrates and toxicity tests, and «determination of 
protective levels and calculations of therapeutic indices by tests on infected 
mice». The agreement included details of the facilities needed to carry 
out the programme: one laboratory for isolation, one for identification, 
a chemical laboratory and a biological laboratory. Those «four screening 
laboratories» needed one supervisor, three to four assistants and a dozen 
technicians. The agreement even laid down the weekly output requirements 
of the programme: 12 soil samples, 500 tested isolates, 30 cultures in shake 
flasks, 6 cultures in fermenters and two new products in animal tests 45. 
The list of duties included in the agreement suggests that there was to 
be a reproduction of a pre-existing pattern: that of Waksman and Merck 
research laboratories working together.
6. Screening research patterns
The programme proved to be «highly productive» in terms of figures of soil 
samples collected, fermented, isolated, concentrated and tested in bacterial 
cultures and in rats. Fifty thousand new isolates per year were tested 46. This 
joint programme relied on biological techniques to identify antimicrobial 
substances. An «antimicrobial spectrum conducted on gradient plates and 
cross-resistance studies with mutants of E. coli» proved especially useful 47. 
According to the microbiologists who worked with the group, methods 
for isolating and testing samples and broths were kept secret 48. However, in 
1958 the group of CEPA researchers published a report in which methods 
quite similar to those described by Waksman in his Nobel lecture of 
1952 were used. The group started to publish the results of the research 
conducted from 1957 onwards in a Spanish journal (Anales del Instituto de 
 45. Agreement, n. 39.
 46. Strohl et al, n. 35. 
 47. Woodruff; Hernández; Stapley, n. 33, p. 75.
 48. On secret and penicillin patents see Romero, this issue.
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Farmacología Española), and in those papers they gave an account of the 
methods used and the antibiotic activity found 49. 
The soil sample was suspended in sterile water and an abundance of 
antagonists using a series of solutions from 1:10 to 1:10.000 were tested. A 
one millilitre portion of these solutions was placed in a Petri dish and the 
bacterial agar prepared beforehand for the trial was added. The presence of 
antagonists was shown by the clear zones formed surrounding the colonies. 
The following step was to dilute soil samples and culture them in shaking 
flasks in a procedure similar to the submerged aerated culture that led to 
efficient yields of penicillin from Penicillium cultures 50. 
To achieve a more concentrated extract of the prospective antibiotic 
substance the broth was treated with charcoal, which absorbed it, and 
was later on diluted with acid so as to extract it back. The antimicrobial 
activity was evaluated by monitoring the activity against a list of gram-
negative bacteria. This was the case of the isolation of a xanthomycin in 
CEPA in 1957 51.
 The main difference between the procedures at CEPA and Merck was 
that at the CEPA laboratories the submerged fermentations, when presenting 
any antibiotics activity, were tested on mice. Therapeutic activity was 
studied by intra-peritoneal injection and by later sacrificing the animal to 
check for toxicity in the organs. Local regulations did not prevent the use 
of laboratory animals as they did in New Jersey at that time 52.
7. Research in the factory
This modern style of producing new substances, or samples that might 
contain them, evokes that of early industrial production: the integration 
of workshops under the same roof, supervised by a person in charge of the 
 49. Martínez Mata, J.; Hernández, S.; Mochales, S.; Maldonado, F.; Moreno, A.; Gallego, A. Un programa 
de investigación de nuevos antibióticos II. Aislamiento y caracterización de una xantomicina 
antibiótico 1561 (4). Anales del Instituto de Farmacología Española. 1958: 267-270.
 50. Waksman, Selman; Woodruff, W. Boyd. The soil as a source of microorganisms antagonistic 
to disease-producing bacteria. Journal of Bacteriology. 1940; 40: 581-600.
 51. Hernández, S.; Mochales, S.; Martínez Mata, J.; Gallego, A. Un programa de investigación de 
nuevos antibióticos. I. Resultados del año 1957. Anales del Instituto de Farmacología Española. 
1958: 263-266.
 52. Swann, n. 36. 
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whole process. One person took the sample and sent it to the programme 
site (CEPA, Madrid); a second did the first step, from which came the 
second and successive steps so that, in the end, something new, active and 
non-toxic was achieved. It was a process of progressive selection with a 
pyramidal appearance. The final successful product remained at the top, 
showing an increasingly important, sensitive procedure in order to obtain 
an active sample. 
The way in which research was done systematically, by a line of tasks, 
as I said, can be perceived as routine. It also evokes industrial, assembly-
line manufacturing of successive artisanal works —no automatic procedures 
were in use, just a line of manual tasks establishing standard hand-made 
procedures that could be reproduced elsewhere. Those interactions show a 
landscape in which research agendas and industrial, manufacturing needs 
shared both experts and expertise and, what may have been more relevant, 
these two professional spaces shared interests and modes of production.
The whole project was attuned to other screening programs of the 
time: PKU (phenylketonuria) screening in newborns as well as cancer 
viruses screening were started at the same time. Screening evokes, on one 
hand, war time efforts of systematically searching for solutions to military 
problems or concerns and, on the other, a legacy of chemistry and of earlier 
strategies developed in Germany which finally produced sulfa drugs 53.
At the same time, it was a production line where training was involved: 
tasks functioned as a means of invention while keeping the activity as part 
of a pre-design line. The production line was created as part of a factory; it 
was attuned to the factory system. The factory and the research programme 
exchanged means of production. Homogenisation was part of a culture 
that included research-programme ways of working, of assembling a set 
of tasks in search of new products within the factory space. This work 
distribution of the research programme and the factory were mutually 
consistent: they shared an industrial production culture as well as space 
in the manufacturing plant. 
 53. On PKU, see Paul, Diane. PKU and procreative liberty: historical and ethical considerations. 
Philosophy and Medicine. 2002; 65 (part II): 171-190. See also Paul, Diane; Edelson, Paul J. 
The struggle over metabolic screening. In: De Chadarevian, Soraya; Kamminga, Harmke, eds. 
Molecularizing biology and medicine. New practices and alliances. Amsterdam: Harwood; 
1998, p. 203-220. On screening of cancer viruses, see Löwy; Gaudillière, n 8, and Gaudillière, 
n. 16. On sulfa drugs, see Lesch, n. 13.
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The soils were a source of microbes as well as a source of their 
antagonists. This particular practice of the search for new antibiotics was 
normal at that time: one that specifically integrated the expertise Waksman 
provided to Merck. CEPA’s research laboratory had an artisanal way of 
working and carefully observing broths, antimicrobial activity and managing 
the uniqueness of each new sample and each microorganism found 54. The 
research space was set within the quality control laboratory and was the 
result of interaction between different professional cultures. 
8. At work
By 1957, the CEPA research laboratory was working at full steam. More 
than 95,000 plates of soil samples had led to isolation and fermentation tests 
being conducted on 22,000 of them. These samples were contaminated by 
Neurospora in January and in June. To check their antimicrobial activity, the 
isolated broths were tested against a select list of germs. They were searching 
for antibiotics showing activity against bacteria that had been resistant to 
previously developed antibiotics, mostly Gram-negative bacteria such as 
Staphilococus aureus. Inactive samples and those active against Gram-positive 
bacteria were discarded. Thirty percent of the samples were active. Further 
identification by chromatography led to 126 being discarded, and the 41 
left were tested in a third fermentation against E. coli strains. From them, 
three new neomycine, one xanthomycine and two unknown antibiotics were 
identified. Those samples, previously concentrated, were sent to Rahway, in 
whose research laboratories the substances were purified and identified. The 
small group of researchers enjoyed their work and introduced modifications 
to improve methods of isolation and identification 55.
At some point, by the late 1960s, further chemical and microbiological 
studies on the concentrate were fed into a computer in order to compare 
them with all the antibiotics already identified. «The machine excludes 
normally more than 90 per cent of the broths and kept a small residue of 
them really productive of new antibiotic substances». In other words, the 
machine accepted very few new products as antibiotics. Most of the samples 
 54. Mochales interview.
 55. Hernández; Mochales; Martínez Mata; Gallego, n. 51.
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whose characteristics were introduced into the machine were considered by 
the program to not be new, meaning they had already been characterised 56.
Computerization became the «obvious answer» to the problem of 
identifying a product as new, at a time when the catalogue of antibiotics 
was fast increasing in size. From more than 300 listed in 1957, by the late 
1970s the number rose to 2,400. Each antibiotic known was then fed into 
a computer programme and its properties allowed every new finding to be 
checked, by comparing its properties with those of the antibiotics stored «in 
the memory bank». Computer technology in this case involved gathering 
the known antibiotics and classifying them according to selected properties. 
Later on, the computer was programmed «as a learning machine» 57.
By means of this research programme at CEPA, Merck shifted the major 
screening to Spain and initiated new fields of research in Rahway, such as 
one on the attack of dental caries 58.
The screening work based on natural products continued until 2006, 
when Merck closed what was by then a 50 year-old research centre on natural 
products. During its history, a set of antibiotics was identified and three 
of them went onto the market: fosfomycin, cephamycin and thienamycin. 
Fosfomycin was developed by CEPA in Spain. Cephamycin and thienamycin 
derivatives were marketed by Merck. Cephamycin C led to the development 
of semisynthetic cephalosporin, cefoxitin, widely used in hospitals in the 
1980s. Thienamycin derivative was marketed and used to treat bacterial 
infections in hospitals. Further drugs identified as part of this program at 
CEPA research laboratory were the statins used to control atherosclerosis 
and cardiovascular risk. Later on, antifungals were among the type of drugs 
isolated by what in 1980 became a research centre, CIBE 59.
 56. Martínez Mata, Justo. La investigación de antibióticos en la industria farmacéutica española. 
Historia de un descubrimiento: la fosfomicina. Química e Industria. 1974; 20: 51-59.
 57. Woodruff; Hernández; Stapley, n. 33. On data base’ construction and computers, see also 
García-Sancho, Miguel. From metaphor to practices: the introduction of information engineers 
into the first RNA sequence database. History and Philosophy of the Life Science. 2011 (in 
press).
 58. Woodruff, H. Boyd. A soil microbiologist’s odyssey. Annual Review of Microbiology. 1981; 35: 
1-28 (23).
 59. Peláez, Fernando. Introduction: 50 years of CIBE. In: CIBE: 50 años de investigación. Madrid: Merck 
Sharp and Dhome España; 2005, p. 23-33 (p. 24-25). See also Peláez, Fernando. The historical 
delivery of antibiotics from microbial natural products —can history repeat? Biochemical 
Pharmacology. 2006; 71: 981-990.
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9. Concluding remarks
Research standards circulated from one pharmaceutical company to 
another, from one country to another, from a microbiological laboratory 
to a quality-control laboratory, and amongst different professional groups. 
These standards, emerging in a collaborative research program, included 
technical and research skills and entrepreneurial relationships that became 
stabilized. By providing results, concentrates of prospective new antibiotics, 
the antibiotic screening program generated feedback, that is to say, more 
circulation. On this journey, and by crossing national, professional and 
local boundaries, drugs research led to collaboration and the development 
of skills.
In the case presented here, it was a research project that travelled 
and, more broadly, a research agenda which formed part of the biography 
of a firm whose previous and current main function was to manufacture 
antibiotics; that is, to build up an antibiotics factory and keep it functioning. 
Screening was, as I suggest, attached to the factory system and was a result 
of the interactions between two spaces, professional and social. Through 
these spaces, tasks and knowledge circulated and created an intersection, 
the arena in which the particularities of an antibiotic screening program 
developed.
This is a particular case of research done by an industrial firm, a very 
unusual task to be carried out by a firm in Spain in the early 1950s. By the 
end of the first decade of the Franco dictatorship, contracts for industrial 
production were starting to be bought by Spanish entrepreneurs, companies 
and even dictatorship authorities so as to participate in the international 
industrial development that showed promise at that time. Turn-key contracts 
to build-up factories and to manufacture a wide variety of products were 
bought, in what can be regarded as a reaction against the previous compulsory 
autarchy. By the early 1950s, national borders began to be crossed from 
abroad by many companies eager to get into new markets, while Spanish 
entrepreneurs, engineers and scientists had also begun to travel abroad 
for training and to learn about new techniques, especially to the U.S. It 
was indeed the case of the screening program of antibiotics itself, which 
can well be regarded as a turn-key research program which contributed 
to learning and training in a factory, both of the factory workers and the 
personnel involved in microbiological techniques for industrial purposes. 
Production of other new antibiotics came at the same time, and by the mid-
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1950s streptomycin was also being made in Spain by CEPA with another 
Merck patent. 
A question remains as to what extent this screening program was 
contributing to blur the borders that separated industry from research, as 
both were systems of production. The screening research program at CEPA 
in collaboration with Merck couldn’t be understood without the factory. 
Even the agreement between CEPA and Merck for the research program can 
only be understood by recalling that the previous agreement for antibiotic 
manufacturing in Madrid was already in force and well-developed. 
Screening became a way of systematically searching for something, 
either the absence or the presence of a given product (molecule, enzyme, 
antibiotic) in a given set of samples (soil, blood, a mixture of whatever 
origin) 60. Waksman himself was proud of having had a group of assistants 
and students who tested more than 10,000 cultures from various natural 
substrates, ten percent of which showed antibacterial activity, and from 
them, finally, ten antibiotics were submitted for biological evaluation. This 
way of working at Rutgers started in the late 1930s 61.
Finally, I would like to suggest that the industrial nature of CEPA’s 
research laboratory and, by extension, of the screening programme, was 
embedded in, or reverted to, natural history-style collection methods 62. By 
systematically and manually collecting so much information about different 
kinds of cultures, the program integrated not only artisanship in every step, 
as I suggest above, but also, as microbiological collections do, brought natural 
 60. For a wide discussion on screening in relation to standards and regulation see Gaudillière, 
Jean-Paul. The singular fate of industrial screening in twentieth century pharmacy. Some 
thoughts about drug standardisation and drug regulation. In Bonah, Christian; Masutti, 
Christophe; Rasmussen, Anne; Simon, Jonathan, eds. Harmonizing drugs: standards in 20th-
century pharmaceutical history. Paris: Glyphe; 2009, p. 153-180.
 61. Waksmann, Selman. The antibiotic era: a history of the antibiotics and of their role in the 
conquest of infectious diseases. 1975, published posthumously, quoted in Comroe J. H., Jr. Pay 
dirt: the story of streptomycin. I: from Waksman to Waksman. Retrospectroscope. American 
Review of Respiratory Diseases. 1978; 117: 773-781.
 62. On collecting data on molecules for cataloguing, see De Chadarevian, Soraya. Following 
molecules: hemoglobin between the clinic and the laboratory. In: De Chadarevian, Soraya; 
Kamminga, Harmke, eds. Molecularizing biology and medicine. New practices and alliances. 
Amsterdam: Harwood; 1998, p. 171-201. On collecting data on molecules as a natural history 
practice, see Strasser, Bruno. Collecting and experimenting: the moral economies of biologi-
cal research, 1960-1980s. In: History and epistemology of molecular biology and beyond: 
problems and perspectives. Berlin: Max Planck Institut für Wissenschaftsgeschichte; 2006. 
Preprint 310, p. 105-125. 
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history to twentieth century patterns of industrializing drugs research. The 
early meaning of the term screening as a microbiological task included a set 
of artisanal steps, a method of manually collecting data about Actinomycetes, 
and an interaction with the factory system to produce new antibiotics.
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